Cadrenal Therapeutics, Inc. Net Fee Amt
Cadrenal Therapeutics, Inc. (CVKD) had Net Fee Amt of $40.76 as of 2026-08-27, per its S-8 filed 2026-09-03.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-03
- 2026-08-27: Net Fee Amt $40.76.
- 2026-07-08: Net Fee Amt $1.24K.
- 2026-04-15: Net Fee Amt $780.57.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-27 | $40.76 S-8 · filed 2026-09-03 |
| 2026-07-08 | $1.24K S-3 · filed 2026-07-13 |
| 2026-04-15 | $780.57 S-3 · filed 2026-04-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |